Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.795
+0.015 (0.54%)
At close: Jul 20, 2026, 4:00 PM EDT
2.800
+0.005 (0.16%)
After-hours: Jul 20, 2026, 7:48 PM EDT
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $1.30M in the quarter ending March 31, 2026, a decrease of -20.26%. This brings the company's revenue in the last twelve months to $6.32M, down -52.64% year-over-year. In the year 2025, Fate Therapeutics had annual revenue of $6.65M, down -51.24%.
Revenue (ttm)
$6.32M
Revenue Growth
-52.64%
P/S Ratio
51.58
Revenue / Employee
$39,230
Employees
161
Market Cap
325.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.65M | -6.99M | -51.24% |
| Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
| Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
| Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
| Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
| Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
| Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
| Dec 31, 2018 | 4.74M | 634.00K | 15.44% |
| Dec 31, 2017 | 4.11M | -296.00K | -6.72% |
| Dec 31, 2016 | 4.40M | 1.97M | 81.08% |
| Dec 31, 2015 | 2.43M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 971.00K | -1.70M | -63.63% |
| Dec 31, 2012 | 2.67M | 1.50M | 128.21% |
| Dec 31, 2011 | 1.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 217.78M |
| Bicycle Therapeutics | 63.50M |
| OmniAb | 28.94M |
| Foghorn Therapeutics | 28.22M |
| Vicore Pharma Holding AB | 370.61K |
| Lyell Immunopharma | 31.00K |
| Inhibikase Therapeutics | 1.00 |
FATE News
- 11 days ago - Fate Therapeutics announces FDA clearance of FT839 IND application - TheFly
- 11 days ago - Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewsWire
- 14 days ago - Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting - GlobeNewsWire
- 19 days ago - Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - GlobeNewsWire
- 5 weeks ago - Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics management to meet with Piper Sandler - TheFly
- 6 weeks ago - Fate Therapeutics Slides: Corporate presentation - Filings